11.21.22 -- Sanofi Reshapes Patient Experience With Digital Technologies

For years, sponsor companies have had access to new and emerging technologies that would ease the participation burden of patients in clinical trials. While these emerging technologies helped sponsor companies keep their trials on track, they have also been a burden for the clinical sites having to deal with the changes required to keep up with them. Do you know where your sites stand on the adoption of hybrid trials and DCTs?

This article breaks down what sites and sponsors need from site feasibility and how a unified site-sponsor platform can address these needs and improve collaboration. 

The time and energy needed for training is among the many drains that researchers complain about, and the one that clinical trial sponsors have the greatest control over.

Watch this video to learn more about Q² Solutions' genomics laboratory capabilities and follow the journey of a sample from accessioning to data analysis and delivery.

Sanofi has adopted a Patient Informed Research And Development model within the organization. The goal of the model is to work with patients, patient groups, and patient communities to understand the concerns of patients and ensure those voices are heard throughout the company. In this Clinical Leader Live, two clinical executives from Sanofi join chief editor, Ed Miseta, to discuss the new R&D model, the company’s attempts to make its trials more patient-centric, and how digital technologies and devices are helping to create a better trial experience for patients.

Discover why clinical trials are quickly becoming more participant-friendly (and more provider-friendly) through the broader adoption of digital technologies.

What makes a clinical trials software provider a good fit? How do you make the decision to use a particular electronic data capture (EDC) system or electronic patient reported outcome (ePRO) solution? Learn how the answers are different for every sponsor and contract research organization (CRO).

Listen to the voice of a patient explain the effects of participating in a decentralized clinical trial and how this impacted his life going forward.

Intersectionality is the framework for how a person’s relationships, identities, interactions, and interdependencies can create different advantages and disadvantages. In order to fully embrace intersectionality and make meaningful impacts in clinical trial recruitment of diverse populations, the entire journey of the patient must be realized every step of the way.

The U.S. Food and Drug Administration (FDA) published its Novel Drug Approvals Report for 2021. Thirty-three out of 50 drugs underwent clinical trials in Eastern Europe. Read the annual Industry Pages report from an Eastern European CRO to find out why global pharma considers the region as the best destination for their clinical research activities.

Discover patient and public perceptions, and how the industry is evolving to deliver an improved clinical trial participant experience.

With PCM Trials, our experienced certified mobile research nurses (CMRNs) travel directly to your trial participants, wherever they may be ― at home, work, school, care center, vacation, anywhere. PCM can adapt with your study design.